Key Findings
The European market for pain management drugs is growing at a CAGR of 3.96% during the forecasting years 2019-2027. The United Kingdom, Germany, France, Italy, Spain & the collective countries from the Rest of Europe are considered for the market study. The availability of sophisticated treatment options has led to an increase in the geriatric population who are more dependent on pain management medications.

MARKETING INSIGHTS
Rising cases of cancer pain indication are expected to drive the European market during the forecasting period. Also, opioids drugs will have the highest sales in the Europe market shortly. Major market players in Europe are exhausting advanced technology for the developing abuse-deterrent drugs due to the increase in the number of drug abuse cases in the region. The mounting numbers of surgical procedures coupled with growing healthcare expenditure will be driving the market growth in Germany, whose market is expected to be the dominating one in terms of revenue by the end of 2027.

Competitive Insights
The major competing companies in the Europe pain management market are Daiichi Sankyo, Inc., Novartis, Egalet Corp., Eli Lilly and Company, Purdue Pharma L.P., Insys Therapeutics, Inc., GlaxoSmithKline, Abbott Laboratories, Hikma Pharmaceuticals PLC, Johnson & Johnson, Acura Pharmaceuticals, Inc., Lupin Ltd., Pfizer, Inc., Merck & Co., Inc. and Cipher Pharmaceuticals Inc.